Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth
Summary
GBI Research, the leading business intelligence provider, has released its latest research, Psoriasis Therapeutics in Asia-Pacific Markets to 2021: Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth, which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Researchs team of industry experts.
In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $690m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $1.2 billion. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant patient share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.
Scope
The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes -
- A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms
- In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy
- A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target
- Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type
- Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets
- Discussion of the drivers of and barriers to market growth
- In-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006
Reasons to buy
The report will enhance your decision-making capability by allowing you to -
- Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative
- Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be
- Follow the trends in psoriasis clinical trial size and duration in relation to industry averages
- Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates
- Analyze the potential growth patterns expected for the psoriasis market over the forecast period
- Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers
- Accelerate and strengthen your market position by identifying key companies for strategic partnerships
Table Of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 9
2.1 Symptoms 10
2.1.1 Skin Manifestations 10
2.1.2 Psychological Impact 10
2.2 Etiology, Co-morbidities and Risk Factors 10
2.2.1 Genetics 10
2.2.2 Psoriatic Arthritis 10
2.2.3 Mental Health Disorders 10
2.2.4 Metabolic Syndrome, Smoking, Diet and Alcohol Consumption 11
2.2.5 Infections 11
2.2.6 Köebner Phenomenon 11
2.2.7 Other Immune-Mediated Diseases 12
2.3 Pathophysiology 12
2.4 Diagnosis 12
2.5 Epidemiology 13
2.6 Treatment and Management 14
2.6.1 Pharmacological Therapies 15
2.6.2 Non-pharmacological Therapies 16
2.6.3 Combination and Rotational Therapies 16
2.6.4 Quality of Life Assessments 16
2.6.5 Summary 17
3 Marketed Products 18
3.1 Overview 18
3.2 Methotrexate-Based Products 18
3.3 Sandimmune/Neoral (cyclosporine/modified cyclosporin) – Novartis 19
3.4 Humira (adalimumab) – AbbVie 20
3.5 Enbrel (etanercept) – Amgen 22
3.6 Remicade (infliximab) – Janssen Biotech 24
3.7 Stelara (ustekinumab) – Janssen Biotech 25
3.8 Comparative Efficacy and Safety 27
4 Psoriasis Market to 2021 – Pipeline Products 29
4.1 Overview 29
4.2 Overall Pipeline 29
4.3 Pipeline Analysis by Molecule Type 31
4.4 Pipeline Analysis by Molecular Target 32
4.5 Clinical Trials 34
4.5.1 Overall Failure Rate 34
4.5.2 Failure Rate by Molecule Type 35
4.5.3 Failure Rate by Molecular Target 36
4.5.4 Patient Enrollment and Clinical Trial Size 37
4.5.5 Duration 38
4.5.6 Summary of Psoriasis Clinical Trials 39
4.6 Promising Drug Candidates in the Pipeline 40
4.6.1 LY2439821 (ixekizumab) – Eli Lilly 40
4.6.2 Xeljanz (tofacitinib) – Pfizer 41
4.6.3 Brodalumab – Amgen 42
5 Market Forecast to 2021 44
5.1 Geographical Markets 44
5.1.1 Asia-Pacific Market Overview 44
5.1.2 China 46
5.1.3 India 47
5.1.4 Japan 49
5.1.5 Australia 50
5.2 Drivers and Barriers 52
5.2.1 Drivers 52
5.2.2 Barriers 52
6 Deals and Strategic Consolidations 54
6.1 Major Co-development Deals 54
6.1.1 AbbVie Enters into Co-development Agreement with Biotest for Tregalizumab 58
6.1.2 Lycera Enters into Research Agreement with Merck 58
6.1.3 LEO Pharma Enters into Research Agreement with 4SC Discovery for Inflammatory Skin Diseases 59
6.1.4 Amgen Enters into Co-Development Agreement with AstraZeneca for Five Human Monoclonal Antibodies Including Brodalumab 59
6.2 Major Licensing Deals 60
6.2.1 Leo Pharma Enters into Licensing Agreement with Virobay for Psoriasis Drug 63
6.2.2 Foamix Enters into Licensing Agreement with Dr. Reddy's Laboratories 63
6.2.3 Cipher Pharmaceuticals Enters into Licensing Agreement with IBSA Institut Biochimique for Betesil Patch 64
6.2.4 Phenex Pharmaceuticals Enters into Licensing Agreement with Janssen Biotech for Retinoid-Acid Receptor-Related Orphan Receptor Gamma t Program 64
7 Appendix 65
7.1 All Pipeline Drugs by Phase 65
7.1.1 Discovery 65
7.1.2 Preclinical 67
7.1.3 IND/CTA-Filed 70
7.1.4 Phase I 71
7.1.5 Phase II 74
7.1.6 Phase III 78
7.1.7 Pre-registration 79
7.2 Market Forecasts to 2021 79
7.2.1 Global 79
7.2.2 China 79
7.2.3 India 80
7.2.4 Japan 80
7.2.5 Australia 80
7.3 Market Definitions 81
7.4 Abbreviations 81
7.5 References 82
7.6 Research Methodology 86
7.6.1 Coverage 87
7.6.2 Secondary Research 87
7.6.3 Primary Research 87
7.6.4 Therapeutic Landscape 88
7.6.5 Geographical Landscape 90
7.6.6 Pipeline Analysis 91
7.7 Expert Panel Validation 91
7.8 Contact Us 91
7.9 Disclaimer 91
List Of Tables
1.1 List of Tables
Table 1: Psoriasis Market, Global, Types of Psoriasis, 2015 9
Table 2: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Discovery, 2014 65
Table 3: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 67
Table 4: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 70
Table 5: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 71
Table 6: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 74
Table 7: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 78
Table 8: Psoriasis Market, Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014 79
Table 9: Psoriasis Market, Asia-Pacific, Forecast Data, 2014–2021 79
Table 10: Psoriasis Market, China, Forecast Data, 2014–2021 79
Table 11: Psoriasis Market, India, Forecast Data, 2014–2021 80
Table 12: Psoriasis Market, Japan, Forecast Data, 2014–2021 80
Table 13: Psoriasis Market, Australia, Forecast Data, 2014–2021 80
List Of Figures
1.2 List of Figures
Figure 1: Psoriasis Market, Global, Composite Treatment Algorithm, 2015 14
Figure 2: Psoriasis Market, Global, Humira (adalimumab), Annual Sales ($bn), 2007–2014 22
Figure 3: Psoriasis Market, Global, Enbrel (etanercept), Annual Sales ($bn), 2007–2014 23
Figure 4: Psoriasis Market, Global, Remicade (infliximab), Annual Sales ($bn), 2007–2014 25
Figure 5: Psoriasis Market, Global, Stelara (ustekinumab), Annual Sales ($bn), 2010–2014 26
Figure 6: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (1/2), 2015 27
Figure 7: Psoriasis Market, Global, Comparative Safety and Efficacy of Marketed Products Heatmap (2/2), 2015 28
Figure 8: Psoriasis Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2015 30
Figure 9: Psoriasis Market, Global, Pipeline by Molecule Type and Stage of Development, 2015 31
Figure 10: Psoriasis Market, Global, Pipeline by Molecular Target (1/2), 2015 32
Figure 11: Psoriasis Market, Global, Pipeline by Molecular Target (2/2), 2015 33
Figure 12: Psoriasis Market, Global, Pipeline by Molecular Target, Molecule Type and Stage of Development, 2015 34
Figure 13: Psoriasis Market, Global, Clinical Trial Failure Rate (%), 2015 35
Figure 14: Psoriasis Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2015 36
Figure 15: Psoriasis Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2015 37
Figure 16: Psoriasis Market, Global, Clinical Trial Size, 2015 38
Figure 17: Psoriasis Market, Global, Clinical Trial Duration (months), 2015 39
Figure 18: Psoriasis Market, Asia-Pacific, Treatment Use Patterns and Market Size ($m), 2014–2021 45
Figure 19: Psoriasis Market, China, Treatment Use Patterns, Annual Cost of Therapy ($) and Market Size ($m), 2014–2021 47
Figure 20: Psoriasis Diabetes Market, India, Treatment Use Patterns, Annual Cost of Therapy ($), and Market Size ($m), 2014–2021 48
Figure 21: Psoriasis Market, Japan, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size ($m), 2014–2021 50
Figure 22: Psoriasis Market, Australia, Treatment Use Patterns, Annual Cost of Therapy ($), Market Size ($m), 2014–2021 51
Figure 23: Psoriasis Market, Global, Co-development Deals by Geography, Deals by Value, 2006–2014 55
Figure 24: Psoriasis Market, Global, Co-development Deals by Year, Deals by Phase and Molecule Type, 2006–2014 56
Figure 25: Psoriasis Market, Global, Co-development Deals by Molecule Type and Deal Value, Deals by Molecular Target and Deal Value, 2006–2014 57
Figure 26: Psoriasis Market, Global, Co-development Deals by Geography, 2006–2014 58
Figure 27: Psoriasis Market, Global, Licensing Deals by Geography and Value, 2006–2014 60
Figure 28: Psoriasis Market, Global, Licensing Deals by Year, Licensing Deals by Phase and Molecule Type, 2006–2014 61
Figure 29: Psoriasis Market, Global, Licensing Deals by Year and by Phase, 2006–2014 62
Figure 30: Psoriasis Market, Global, Licensing Deals by Geography, 2006–2014 63
Figure 31: GBI Research Market Forecasting Model (Example) 90
